COVID-19病毒灭活疫苗(中国医学科学院医学生物学研究所)(Inactivated SARS-CoV-2 Vaccine (Vero cell)(Chinese Academy of Medical Sciences)) - 药物靶点：SARS-CoV-2 antigen_在研适应症：新型冠状病毒感染_专利_临床

概要

基本信息

药物类型

预防性疫苗

别名

COVID-19 Inactivated vaccine(Chinese Academy of Medical Sciences)、科维福

靶点

SARS-CoV-2 antigen

作用方式

抑制剂

作用机制

新冠病毒抗原抑制剂

治疗领域

感染呼吸系统疾病

在研适应症

新型冠状病毒感染

非在研适应症-

原研机构

中国医学科学院医学生物学研究所

在研机构

中国医学科学院医学生物学研究所

非在研机构-

权益机构-

最高研发阶段批准上市

首次获批日期

中国 (2021-06-09),

新型冠状病毒感染

最高研发阶段(中国)批准上市

特殊审评紧急使用授权 (中国)

登录后查看时间轴

关联

7

项与 COVID-19病毒灭活疫苗(中国医学科学院医学生物学研究所) 相关的临床试验

NCT05312476

/ Recruiting临床2期IIT

Clinical Study of the Safety, Tolerability and Preliminary Efficacy of Chimeric Antigen Receptor T Cells (CAR-T) Targeting Igβ Targets in Patients With Igβ-positive Refractory Relapsed Non-Hodgkin's Lymphoma

Aim of this study will evaluate the safety, tolerability and preliminary efficacy of chimeric antigen receptor T cells (CAR-T) targeting Igβ targets in patients with Igβ-positive refractory relapsed non-Hodgkin's lymphoma.

开始日期2022-02-10

申办/合作机构

苏州大学附属第一医院

ChiCTR2100054614

/ Recruiting临床4期IIT

Post-Marketing clinical study of inactivated new coronavirus vaccine (Vero cells): Evaluation of immunogenicity and safety in people with hypertension and diabetes

开始日期2021-07-16

申办/合作机构-

ChiCTR2100047917

/ Recruiting临床1期IIT

Comprehensive evaluations of dynamic changes in the immune system of healthy volunteers with sequential vaccination of inactivated Novel Coronavirus Pneumonia vaccine (Vero cells) followed by Novel Coronavirus Pneumonia mRNA vaccine (DF104B1)

开始日期2021-06-21

申办/合作机构

上海市东方医院

100 项与 COVID-19病毒灭活疫苗(中国医学科学院医学生物学研究所) 相关的临床结果

登录后查看更多信息

100 项与 COVID-19病毒灭活疫苗(中国医学科学院医学生物学研究所) 相关的转化医学

登录后查看更多信息

100 项与 COVID-19病毒灭活疫苗(中国医学科学院医学生物学研究所) 相关的专利（医药）

登录后查看更多信息

46

项与 COVID-19病毒灭活疫苗(中国医学科学院医学生物学研究所) 相关的文献（医药）

2024-12-24·Blood Advances

Cardiovascular toxicities associated with novel cellular immune therapies

Review

作者: Epperla, Narendranath ; Addison, Daniel ; Munir, Malak ; Sayed, Ahmed

AbstractOver the past decade, T-cell–directed therapies, including chimeric antigen receptor T-cell (CAR-T) and bispecific T-cell engager (BTE) therapies, have reshaped the treatment of an expanding number of hematologic malignancies, whereas tumor-infiltrating lymphocytes, a recently approved cellular therapy, targets solid tumor malignancies. Emerging data suggest that these therapies may be associated with a high incidence of serious cardiovascular toxicities, including atrial fibrillation, heart failure, ventricular arrhythmias, and other cardiovascular toxicities. The development of these events is a major limitation to long-term survival after these treatments. This review examines the current state of evidence, including reported incidence rates, risk factors, mechanisms, and management strategies of cardiovascular toxicities after treatment with these novel therapies. We specifically focus on CAR-T and BTE therapies and their relation to arrhythmia, heart failure, myocarditis, bleeding, and other major cardiovascular events. Beyond the relationship between cytokine release syndrome and cardiotoxicity, we describe other potential mechanisms and highlight key unanswered questions and future directions of research.

2024-11-01·Journal of VitreoRetinal Diseases

Resolution of Anterior Uveal Infiltration of Acute Lymphoblastic Leukemia After Chimeric Antigen Receptor T-Cell Therapy

Article

作者: Aslam, Rabail ; Kurup, Shree K. ; Oduro, Kwadwo A. ; Mehra, Ankur A. ; Takhar, Jaskirat S. ; Echegaray, Jose J. ; Sobol, Warren M.

Purpose: To present a case of acute B-cell lymphoblastic leukemia (B-ALL) ocular relapse treated with chimeric antigen receptor T-cell (CAR-T) therapy. Methods: A retrospective case review was evaluated. Results: A 69-year-old woman with a history of B-ALL presented with bilateral hypopyons and 3+ anterior chamber cells that responded to topical prednisolone. Six months later, she developed recurrent hypopyons, iris neovascularization, and iris nodularity in both eyes. A fine-needle aspiration biopsy confirmed ocular infiltration of B-ALL. A single infusion of CAR-T therapy resulted in remission of the systemic and ocular findings. The clinical course was complicated by cytokine release syndrome and neurotoxicity, which improved with medical management. The patient remained in remission for 7 months after a single CAR-T infusion. Conclusions: CAR-T therapy may be effective in treating systemic leukemia and uveal infiltration, with a favorable ocular side-effect profile and visual outcomes. The systemic side effects of CAR-T therapy may be managed medically.

2024-07-01·Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology

[Bioinformatic prediction and validation of cellular-mesenchymal epithelial transition(c-Met) as a target for chimeric antigen receptor T (CAR-T) cell therapy in the treatment of colorectal cancer].

Article

作者: Li, Haipeng ; Long, Chirong ; Peng, Shang ; Li, Zhenghon ; Xie, Zilong ; Min, Jingting ; Zhang, Lu

Objective To explore the potential of the cell surface receptor c-Met as an effective target for chimeric antigen receptor T-cell (CAR-T) therapy in colorectal cancer. Methods The bioinformatics was used to analyze the specific expression of c-Met in colorectal adenocarcinoma (COAD) and its clinical significance. c-Met protein expression was detected by immunohistochemistry in tumor tissues obtained from colorectal cancer patients. Flow cytometry was utilized to assess the expression of c-Met in the HCT116 human colorectal cancer cell line. Additionally, primary T cells isolated from human peripheral blood mononuclear cells (PBMCs) were transduced with a lentivirus to generate second-generation CAR-T cells targeting c-Met, followed by an observation of the inhibitory effects of these c-Met-targeted CAR-T cells on HCT116 cells. Results Immunohistochemistry and bioinformatics data both demonstrated that c-Met was over-expressed in COAD, with patients exhibiting relatively lower expression showing better prognosis. In normal colonic tissue, c-Met was either expressed at low levels or not expressed. Flow cytometry revealed high expression of c-Met in HCT116 cells as well. The c-Met-targeted CAR-T cells were capable of specifically recognizing and targeting antigen-expressing tumor cells. CAR-T cells proliferated specifically under antigenic stimulation, exerting cytotoxic effects on cancer cells and releasing cytokines interleukin 2 (IL-2) and interferon-gamma (IFN-γ), thereby demonstrating the biological functions. Conclusion c-Met may be a promising therapeutic target in COAD; c-Met-targeted CAR-T cells demonstrate inhibitory effects on colorectal cancer cells in vitro.

100 项与 COVID-19病毒灭活疫苗(中国医学科学院医学生物学研究所) 相关的药物交易

登录后查看更多信息